TOPIC:  How do Raf inhibitors affect the heart?
FUNDING:  Funding is available from the British Heart Foundation for a post-doctoral research associate for 18 months to increase our understanding of the effects of Raf on heart failure.  
DETAILS:  This project focuses on the effects on the heart of inhibitors of the Raf kinases that signal to ERK1/2.  These drugs are being used to treat cancer.  The first generation Raf kinase inhibitors may not be detrimental to the heart, but the effects of second generation “paradox-breakers” remain to be established.  The effects of such inhibitors will be investigated using appropriate ex vivo (cultured cells and perfused hearts) and in vivo experimental systems.  The project will involve assessment of effects on cell death, signalling and gene expression, in addition to effects on cardiac function and dimensions in models of cardiac hypertrophy and heart failure.  Progressive effects on cardiac function will be assessed by echocardiography.  
The position will particularly suit an experienced post-doctoral researcher with a keen interest in intracellular signalling and/or the molecular mechanisms associated with the development of heart failure. 

You will have:
-    A degree in biochemistry or allied discipline, and a PhD in a relevant discipline
-    Experience in working with in vivo systems
-    An interest in understanding (preferably with training) the in vivo consequences of protein kinase signalling in the heart 
-    Molecular biology and/or protein biochemistry and/or cell biology training and expertise
-    An interest in (preferably with training) intracellular signalling pathways

Interview date: 21 August 2019

The University is committed to having a diverse and inclusive workforce, is a Stonewall Diversity and Global Diversity Champion, and supports the principles of the Race Equality Charter and Athena SWAN.  Applications for job-share, part-time and flexible working arrangements are welcomed and will be considered in line with business needs.